drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
A subcutaneous human afucosylated IgG1 monoclonal antibody (also known as AMG 451/KHK4083) targeting OX40 (TNFRSF4). It blocks OX40–OX40L costimulatory signaling and depletes OX40-expressing activated effector/memory T cells via enhanced ADCC, reducing pathogenic T-cell activation, survival, and cytokine production in atopic dermatitis.
nci_thesaurus_concept_id
C184936
drug_mesh_term
KHK4083
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Afucosylated human IgG1 monoclonal antibody against OX40 (TNFRSF4) that blocks OX40–OX40L costimulatory signaling and depletes OX40-expressing activated effector/memory T cells via enhanced ADCC, thereby reducing T‑cell activation, survival, and inflammatory cytokine production in atopic dermatitis.
drug_name
Rocatinlimab
nct_id_drug_ref
NCT05882877